Clinical Trial Detail

NCT ID NCT03208712
Title Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Michigan Cancer Center
Indications

transitional cell carcinoma

Therapies

Atezolizumab + Radium Ra 223 dichloride

Age Groups: adult senior

No variant requirements are available.